Tactile Systems Technology TCMD 深 滬
等待開盤 08-10 09:30:00 美东时间
29.50
+0.640
+2.22%
華盛通- 最 高29.53
- 今 開28.90
- 成交量 16.13万股
- 最 低 28.66
- 昨 收 28.86
- 總市值 66.54万
- 52周最高 37.77
- 市盈率 靜 36.01
- 換手率 0.71%
- 52周最低 12.25
- 委 比 23.57%
- 總股本 2.26万
- 歷史最高 76.63
- 量 比 0.97
- 振 幅 3.01%
- 歷史最低 6.28
- 每 手 1
- 風險率 6.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
Tactile Medical announced it will release its Q2 2026 financial results on August 10, 2026, after market close. A conference call with Q&A will follow at 5:00 p.m. ET on the same day. Participants can dial 877-407-3088 (or 201-389-0927 for international callers) using access code 13761142. A live webcast will be available on investors.tactilemedical.com, with a replay accessible for two weeks. The company specializes in at-home therapies for chro...
07-21 20:05
Tactile Medical Expands VA and DoD Compression Offering
Tactile Systems Technology ( ($TCMD) ) has issued an update. On July 13, 2026, ...
07-14 01:22
Tactile Systems Enters Into Exclusive Distribution Agreement With ElastiMed To Bring MyoSleeve To Department Of Veterans Affairs And DoD Patients Across US
Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced it has entered into an exclusive distribution agreement with ElastiMed, Inc. to bring MyoSleeve™, its discreet, weara...
07-13 20:02
Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients
Tactile Medical has entered into an exclusive distribution agreement with ElastiMed to bring the MyoSleeve, a discreet, wearable compression device for the lower leg, to VA and DoD patients in the U.S. MyoSleeve uses electroactive polymer technology to deliver dynamic compression without tubing or cords, offering a new treatment option for patients in earlier stages of chronic swelling. The device has received FDA clearance and is available by pr...
07-13 12:00
10 Stocks That Prove Good Beats Perfect
There is a line from Epictetus that I have thought about more times than I can count over thirty years of doing this work. He said, “Make the best use of what is in your power, and take the rest as it happens.” Most investors are waiting for perfect. They want every indicator green, every box checke...
06-27 05:20
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Tactile Medical launched the next-generation AffloVest HFCWO therapy system, offering enhanced comfort, connectivity, and ease of use for patients with chronic respiratory conditions like cystic fibrosis and bronchiectasis. The system features a lighter, more adjustable vest, built-in Wi-Fi and Bluetooth, and a user-friendly controller, supporting long-term therapy adherence. Designed with input from patients, clinicians, and DME partners, the ne...
06-02 12:00
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
BTIG Reiterates Buy on Tactile Systems Tech, Maintains $40 Price Target
BTIG analyst Ryan Zimmerman reiterates Tactile Systems Tech (NASDAQ:TCMD) with a Buy and maintains $40 price target.
05-21 18:16
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical announced that its management will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL, from June 2-4, 2026. Management will present on June 2 at 9:20 a.m. Central Time. A live audio webcast will be available on the Company's investor relations website, with an archive for replay post-conference. Tactile Medical focuses on developing at-home therapies for chronic conditions, collaborating with clini...
05-20 20:05
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
